All Stories

  1. Modern Diagnostics of Borderline Personality Disorder: the Relationship between Categorical and Dimensional Approaches
  2. Protein Kinase Expression of the AKT/mTOR Signaling Pathway in Peripheral Mononuclear Cells of Schizophrenia Patients: A Pilot Study
  3. Diagnosis of anxiety and depressive states in alcohol dependence: agreement between clinical assessment and patient self-assessment
  4. Myeloperoxidase, Cathepsin D, and Plasminogen Activation Inhibitor Type 1 as Potential Biomarkers of Schizophrenia (pilot study)
  5. Аминодигидрофталазиндион натрия в комплексной терапии пациентов с алкогольной зависимостью
  6. Predicting the risk of the formation of mixed anxiety and depressive disorders in women
  7. Quantitative electroencephalogram in females at different stages of alcohol remission
  8. Suicidal risk in bipolar affective disorder taking into account its comorbidity with alcohol addiction
  9. Клинические, социальные и психологические факторы эффективности становления ремиссии при алкогольной зависимости
  10. Academic Psychiatric School in Siberia: History of Formation and Horizons of Development. Interview with an Academician of RAS Nikolay A. Bokhan
  11. COVID-19 anxiety predicts loneliness among university students: the mediating roles of mattering, fear of not mattering, and anti-mattering
  12. The impact of the hypothalamic-pituitary-thyroid axis hormone levels on suicide risk in patients with schizophrenia
  13. Иммунобиологическая модель диагностики течения расстройства адаптации у женщин
  14. Исследование влияния технологии виртуальной реальности на психоэмоциональное состояние здоровых добровольцев
  15. The influence of gender on the clinical and dynamic indicators of alcohol dependence, the level of aggression of patients taking into account comorbidity with affective disorders
  16. Influence of Comorbidity of Depressive Disorders with Alcohol Dependence on the Main Clinical and Dynamic Characteristics of Depression and the Manifestations of Aggressiveness
  17. Indicators of the background spectral power of the EEG in patients with alcohol dependence complicated by exogenous organic brain disease
  18. Features of structural and functional changes of the brain in patients with schizophrenia
  19. Phenotypic Characteristics of Peripheral Blood Lymphocytes in Patients with Alcohol Dependence in the Dynamics of the Post-Abstinence State
  20. Influence of pharmacotherapy on function of biotransformation of xenobiotics liver in patients with neuropsychiatric disorders
  21. Cariprazine in Hospital Treatment of Acute Psychotic Conditions Due to Comorbid Schizophrenia and Chemical Addictions
  22. Association of Peripheral Markers of Oxidative Stress with Clinical Parameters and Inflammatory Factors in Alcoholic Patients
  23. Alcohol-Induced Activation of Chemokine System and Neuroinflammation Development
  24. Halonal, an original benzoylated phenobarbital derivative anticonvulsant: in vivo evaluation, chemometric and molecular docking studies of enantiomers
  25. Иммунологические маркеры прогнозирования затяжного течения расстройства адаптации у женщин с гипотиреозом
  26. Взаимосвязь тромбоцитарных факторов роста с клиническими и клинико-динамическими характеристиками у пациентов с аффективными расстройствами
  27. Features of the Background EEG of Alcohol Dependent Patients with Comorbid Exogenous Organic Brain Damage
  28. Prevalence and risk factors of non-suicidal self-injury behavior
  29. The relationship between the functional state of the brain and clinical and constitutional factors in schizophrenia
  30. Cerebral hemodynamic disorders in patients with schizophrenia with concomitant metabolic syndrome
  31. Electroencephalographic differences in patients with paranoid schizophrenia with or without a history of suicide attempts
  32. Перекрёстное психометрическое исследование пациентов с параноидной шизофренией с наличием или отсутствием суицидальных попыток в анамнезе
  33. Этнокультуральные исследования в Сибири и на Дальнем Востоке (25 лет Международной ассоциации этнопсихологов и этнопсихотерапевтов)
  34. Sleep structure in adults with recurrent epileptic seizures of remote symptomatic etiology
  35. NOS1AP Gene Variants and Their Role in Metabolic Syndrome: A Study of Patients with Schizophrenia
  36. Pilot Study of the DRD3, GHRL, FTO, LEPR, INSIG2, GSTP1, and ABCB1 Gene Expression in Peripheral Blood Leukocytes in Schizophrenic Patients with Metabolic Syndrome
  37. Untargeted Plasma Metabolomic Profiling in Patients with Depressive Disorders: A Preliminary Study
  38. The effectiveness of the original anticonvulsant Galodif® — a GABAA receptor modulator for alcohol withdrawal syndrome
  39. Иммунобиологическая модель дифференциальной диагностики расстройства адаптации и органического эмоционально лабильного расстройства
  40. Influence of Alcohol Dependence on the Clinical and Dynamic Characteristics of Bipolar Disorder with Their Comorbidity in Psychiatric Hospital Patients
  41. Associations between components of metabolic syndrome and cognitive impairment in patients with schizophrenia
  42. Growth factors PDGF-AA, PDGF-BB and BDNF as potential differentiating biomarkers of unipolar and bipolar depression
  43. A pilot study of associations of markers of glial and neuronal degeneration with executive functions in alcohol use disorders
  44. COMPARATIVE ANALYSIS OF ALCOHOL DEPENDENCE AND COGNITIVE DISORDERS IN WOMEN ACROSS DIVERSE ETHNIC POPULATIONS
  45. Innovative Technology of the Self-Emulsifying Drug Delivery System of the Anticonvulsant Galodif
  46. Mental disorders in cerebral paroxysms of epileptic origin
  47. Hormones, oxidized proteins, and lipids in alcoholism. Duration of remission
  48. Development of alcohol dependence and cognitive functioning impairments in women of Tuvan and Russian ethnicity
  49. Динамика алкоголизма в Сибирском и Дальневосточном регионах в зависимости от доходов потенциальных потребителей (1999-2019 гг.)
  50. Клиническая характеристика проявлений боевой психической патологии у комбатантов
  51. An Innovative Stress-Protective and Detoxification Substance for Reducing the Central Nervous System Effects of Alcohol Intoxication
  52. EEG alpha band characteristics in patients with a depressive episode within recurrent and bipolar depression
  53. Relationship of Neurospecific Serum Proteins with Clinical Features in Depressive Episode and Recurrent Depressive Disorder
  54. Serum Levels of S100B Protein and Myelin Basic Protein as a Potential Biomarkers of Recurrent Depressive Disorders
  55. Association of Single Nucleotide Polymorphisms of Cytokine Genes with Depression, Schizophrenia and Bipolar Disorder
  56. Building Predictive Models for Schizophrenia Diagnosis with Peripheral Inflammatory Biomarkers
  57. A novel urea derivative anticonvulsant: In vivo biological evaluation, radioreceptor analysis of GABAA receptors and molecular docking studies of enantiomers
  58. Миграционные потоки: транскультуральные аспекты психического здоровья (обзор зарубежной литературы)
  59. Оценка уровня реабилитационного потенциала у пациентов с психозами, ассоциированными с употреблением современных синтетических психоактивных веществ
  60. EEG Frontal Asymmetry in Unipolar and Bipolar Depression
  61. Genome-wide gene expression responses to experimental manipulation of Saccharomyces cerevisiae repressor activator protein 1 (Rap1) expression level
  62. Когнитивная копинг-терапия алкогольной зависимости и невротических расстройств у пациентов с суицидальными мыслями
  63. Формирование нейрональных элементов нейроиммунной системы эмбрионального мозга человека при пренатальном влиянии алкоголя
  64. Serum Growth Factors in Schizophrenia Patients
  65. Incidence Rate of Nicotine Addiction in University Students of Tomsk
  66. Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
  67. Neurospecific Proteins as Transdiagnostic Markers of Affective Disorders
  68. The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
  69. Association of Non-Suicidal Self-Harm with Anxiety, Depression and Aggressive Behavior in Young Men of Military Age
  70. Treatment of Acute Drug-Induced Psychoses, Associated with Modern Synthetic Psychoactive Substances
  71. Coherence of the electroencephalogram and peripheral markers of nerve tissue damage in depressive disorders
  72. Disorders of cognitive decision-making mechanisms related to reward in alcohol use disorders
  73. Features of the reward-based decision-making in patients with alcohol use disorders
  74. Structural changes in human brain tissue during prenatal alcoholization at different stages of intrauterine development
  75. Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
  76. Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
  77. Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
  78. https://svpin.org/index.php/menujournal-ru/62-zhurnal-za-2022-god/stati-za-2022-god/489-osobennosti-psikhologicheskogo-reagirovaniya-meditsinskikh-rabotnikov-psikhiatricheskogo-statsionara-na-izmenenie-uslovij-professionalnoj-deyatelnosti-v-stressornoj...
  79. Реабилитация в аддиктивных психотерапевтических сообществах психически больных с коморбидным злоупотреблением синтетическими каннабиноидами
  80. Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity
  81. The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
  82. The habenular volume and PDE7A allelic polymorphism in major depressive disorder: preliminary findings
  83. Comorbid Mental Disorders and Quality of Life in Patients with Social Phobia
  84. Late Diagnostics of Bipolar Disorder: Impact on Main Characteristics of Disease, Suicidal Behaviour and Social Adaptation Level of Patients
  85. Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
  86. Факторы риска суицидального поведения при биполярном аффективном расстройстве
  87. Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
  88. Cytokine Production in Whole Blood Cells Culture of Patients with Alcohol Dependence and Autologous Plasma Oxidative Stress Markers
  89. Психологические факторы, наносящие транснациональный урон общественному психическому здоровью населения в период пандемии
  90. Возможные нейрофизиологические маркеры для дифференциальной диагностики биполярных и униполярных аффективных расстройств
  91. Формирование алкогольной зависимости у женщин тувинской и русской этнической принадлежности
  92. Anhedonia as target symptom in personalized therapy of patients with mood disorders and alcohol use disorder comorbidity
  93. Anxiety level and EEG indicators in alcohol dependence: a model for predicting the duration of therapeutic remission
  94. Cerebral hemodynamics and executive functioning in patients with alcohol use disorders
  95. Cognitive features of patients with bipolar disorder in comorbidity with alcohol use disorders
  96. Current methods for predicting therapeutic response in patients with depressive disorders
  97. Frequency of interictal epileptiform discharges in slow sleep with relapse of tonic-conical seizures in adults with generalized epilepsy after withdrawal of antiepileptic drugs
  98. Quantitative characteristics of the alpha-band of the electroencephalogram in people with alcohol dependence
  99. The differential diagnosis of unipolar and bipolar depression based on EEG signals
  100. A New Paradigm to Indicate Antidepressant Treatments
  101. Quantitative characteristics of the alpha-rhythm of the electroencephalogram in depressive disorders
  102. Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression
  103. P.0007 Concentration of BDNF and NSE in blood serum of patients with alcohol use disorder with and without comorbid mood disorders
  104. P.0579 Pharmacogenetic study to elucidate putative dopaminergic mechanisms of antidepressant action
  105. Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design
  106. Estimation of the effect of lithium salts on cytokine production by blood cells in in vitro experiments
  107. Incidence rate and clinical characteristics of seasonal affective disorders in senior medical students
  108. Association of PIP4K2A Polymorphisms with Alcohol Use Disorder
  109. Bipolar Disorder: Comorbidity with Other Mental Disorders
  110. Clinical-Dynamical Features of Alcohol Use Disorder and Mood Disorders Considering the Chronology of Their Comorbidity Formation
  111. Показатели иммунитета, тревожность и соматическая патология как факторы формирования затяжного течения панического расстройства
  112. Психическое здоровье семьи: научно-исторический контекст и актуальные исследования томских ученых
  113. Correlation of Antibodies to Neurotransmitters in the Sera of Women with Alcohol Dependence and Depressive Disorders
  114. Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
  115. Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
  116. Влияние исполнительного функционирования на суицидальное поведение при коморбидности алкогольной зависимости и аффективных расстройств
  117. Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
  118. Clinical characteristics and efficiency of antidepressant therapy of mood disorders with comorbid alcohol use disorder
  119. Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
  120. Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction
  121. Electroencephalographic Markers of Depressive Disorders Resistance to Pharmacotherapy and Determination of a Possible Approach to Individual Prognosis of Therapy Effectiveness
  122. Mental Disorders Associated with the Abuse of Synthetic Cannabinoids (Spices)
  123. Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
  124. An innovative anticonvulsant - a GABAA receptor modulator with an alternative mechanism of action and enzyme-inducing detoxifying properties
  125. Biological profile of medical response in alcoholic patients of different ethnic groups in Siberia
  126. Clinical dynamics of anhedonia symptom in mood disorder and in alcohol use disorder
  127. Neuroendocrine factors - predictors of the formation of alcohol dependence and human ecology in various ethnic populations, new approaches to therapy
  128. Психические нарушения, развивающиеся в кризисно-экстремальной ситуации пандемии коронавируса: актуальная проблематика и особенности психолого-психотерапевтического консультирования
  129. Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
  130. A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia
  131. An Innovatory GABA Receptor Modulator and Liver Oxidase System Microsomal Cytochrome P450 Activator in Patients with Alcoholism
  132. Features of brain activity in alcohol dependence in the task of inhibitory control
  133. Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study
  134. ALCOHOL DEPENDENCE OCCURRENCE AND COGNITIVE COPING PREVENTIONIN STUDENTS AND YOUNG SPECIALISTS
  135. Cognitive impairment in patients after COVID-19
  136. DYNAMICS OF THE PSYCHOPATOLOGICAL PICTURE OF PSYCHOSIS DEVELOPED IN THE BACKGROUND OF THE CONSUMPTION OF MODERN SYNTHETIC PSYCHOACTIVE SUBSTANCES
  137. Normative Assessment of Cognitive Functions with on the Brief Assessment of Cognition In Schizophrenia (BACS) Scale in the Tomsk Population: Constitutional Factors of Variability
  138. Peripheral Markers of Nervous Tissue Damage in Addictive and Affective Disorders
  139. Possible clinical and electroencephalographic factors for predicting the duration of remission in patients with alcohol dependence
  140. SPATIAL DISTRIBUTION OF BIOPOTENTIALS AND THEIR SOURCES IN BRAIN STRUCTURES IN alcohol-dependent patients WITH COMORBID AFFECTIVE DISORDER
  141. Влияние когнитивных функций на уровень суицидального риска у больных шизофренией
  142. Using the quantitative EEG method in predicting the response to treatment of affective disorders
  143. Взаимосвязь цифровых маркеров онлайн-активности и социально-демографических характеристик лиц призывного возраста с несуицидальными формами самоповреждающего поведения
  144. P.541 Inflammation in schizophrenia with metabolic syndrome: features of the cytokine spectrum
  145. P.583 Polymorphisms in BDNF, AKT1, GSK3B genes: possible association with antipsychotic-induced hyperprolactinemia in schizophrenia patients
  146. P.552 Acylcarnitine levels in paranoid schizophrenia with metabolic syndrome during treatment of second-generation antipsychotics
  147. P.514 Contribution of polymorphic variants of MAO genes into prolactin levels in patients with schizophrenia under risperidone therapy
  148. P.182 Metabolic syndrome in patients with schizophrenia and the PTPN5 gene encoding the striatal-enriched protein tyrosine phosphatase
  149. P.513 Metabolic syndrome in schizophrenia and polymorphic variants of CYP1A2 and GSTP1 genes
  150. P.170 Polymorphisms of serotonergic system genes and their association with remission in patients with depression
  151. P.235 S-100, MBP and glial fibrillary acidic protein (GFAP) in patients with mood disorders and alcohol use disorder
  152. P.568 Trihexyphenidyl in combination with antipsychotic therapy does not affect the severity of neurocognitive deficits in patients with schizophrenia
  153. Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
  154. Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia
  155. Genetic polymorphisms of PIP5K2A and course of schizophrenia
  156. Cognitive Changes in Comorbidity Alcohol Dependence and Affective Disorders
  157. Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
  158. Психологические факторы формирования суицидального поведения при обсессивно-компульсивном и социальном тревожном расстройстве
  159. Формирование суицидальности у молодых пациентов с аддиктивными и невротическими расстройствами: социально-психологические факторы риска и психотерапия
  160. NRG1, PIP4K2A, and HTR2C as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder
  161. Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia
  162. Обзор исследований несуицидальных форм самоповреждений по шкалам и опросникам NSSI
  163. Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
  164. 5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
  165. Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression
  166. Affective disorders in comorbidity with alcohol addiction: clinical and dynamic features, social adaptation level of patients
  167. Correction to: Clinical-Dynamic Features of Affective Disorders Comorbid with Alcohol Dependence
  168. Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia
  169. Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
  170. Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
  171. Clinical-Dynamic Features of Affective Disorders Comorbid with Alcohol Dependence
  172. Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
  173. Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy
  174. Clinical value of comorbidity of affective disorders and alcohol dependence
  175. Incidence rate of anxiety and personality disorders and their interrelationship in senior-year students of the medical university
  176. Magnetic resonance spectroscopy in Parkinson’s disease
  177. Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?
  178. Hormones of stress-response system in alcohol dependence: the ability to predict duration of remission
  179. Relationship of cognitive disorders with clinical features of alcohol dependence
  180. Therapy of patients with breast cancer with anxiety and depressive disorders
  181. WITHDRAWAL SYNDROME IN SYNTHETIC CANNABINOID DEPENDENCE ASSOCIATED WITH MENTAL DISORDERS
  182. Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression
  183. Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients
  184. P.390 Characteristics of metabolic hormones in patients with schizophrenia with antipsychotic-induced metabolic syndrome
  185. P.505 The potential role of BDNF and prolactin genotypes on antidepressant response in depressive patients
  186. P.072 Proteomic approach in schizophrenia and bipolar disorder
  187. P.876 The effect of atypical antipsychotic therapy on hormonal and biochemical parameters in patients with schizophrenia
  188. Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
  189. Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
  190. Доля наркозависимых среди завершённых суицидов
  191. Суицидальное поведение больных шизофренией с метаболическим синдромом
  192. Neurocognitive deficits in clinical polymorphism of schizophrenia: typology, expression and syndromal overlaps
  193. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
  194. The difference in serum proteomes in schizophrenia and bipolar disorder
  195. Protective Effects of Pyruvic Acid Salt Against Lithium Toxicity and Oxidative Damage in Human Blood Mononuclear Cells
  196. Суицидальное и парасуицидальное рискованное поведение среди высокообразованной молодежи: дихотомия формирования и дифференцированные возможности когнитивно-поведенческой копинг-терапии
  197. Суицидальные действия наркозависимых: вопросы системного выявления и учёта
  198. A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
  199. The Protective Action of Carnosine and Organic Lithium Salts against Ethanol-Induced Oxidative Damage of Blood Plasma Proteins and Lipids of Healthy Persons and Alcoholic Patients
  200. Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium
  201. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors
  202. SIRT1 Allele Frequencies in Depressed Patients of European Descent in Russia
  203. Disorders of spatial working memory in affective disorders with mild current depression and their neurophysiological correlates
  204. No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia
  205. Protective action of carnosine and organic lithium salts in case of ethanol-induced oxidative damage of proteins and lipids of blood plasma in healthy persons and alcoholic patients
  206. Apolipoprotein serum levels related to metabolic side effects in patients with schizophrenia
  207. Genes of neurotrophic factors and responsiveness to antidepressive psychopharmacotherapy in patients with depressive disorders
  208. Brain pathology in schizophrenia: association with clinical and constitutional factors
  209. DEVELOPMENT OF ADDICTIVE BEHAVIOR IN ADOLESCENT FEMALE STUDENTS FROM COMPREHENSIVE AND CORRECTIVE BOARDING SCHOOLS
  210. Effects of antipsychotic therapy on lipid and carbohydrate metabolism of schizophrenic patients
  211. NEUROPHYSIOLOGICAL FEATURES OF PATIENTS WITH DIFFERENT RATES OF ALCOHOL DEPENDENCE DEVELOPMENT
  212. Parameters of immunity and level of cortisol in schizophrenic patients under long-term therapy with risperidone
  213. Prediction of visceral obesity in schizophrenic patients under therapy with antipsychotics
  214. Quantitative assessment of gray matter changes in patients with schizophrenia by MRI approach
  215. Stress hormones in men whose professional activities are either office-based or of an extreme emergency nature
  216. The role of neuroendocrine factors in the formation of alcohol dependence and human ecology in different ethnic populations: new approaches in therapy
  217. Time course of cognitive dysfunction and biochemical marker of CNS lesions S100ß in coronary artery bypass graft
  218. Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy
  219. Связь суицидального поведения и безнадёжности с акатизией у больных шизофренией
  220. Суицидальное поведение больных биполярным аффективным расстройством при коморбидных психических заболеваниях
  221. Blood-Serum Glutamate in Patients with Depressive Disorders as a Potential Peripheral Marker of the Prognosis of the Effectiveness of Therapy
  222. IgG antibodies from the sera of patients degrade myelin basic protein
  223. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia
  224. Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning
  225. Depressive disorders in women of climacteric age (review of foreign literature for 2012–2016)
  226. The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
  227. Interplay between the key proteins of serotonin system in SSRI antidepressants efficacy
  228. Inflammatory factors and immunophenotypes in adjustment disorders
  229. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine
  230. Association between P-glycoprotein polymorphisms and antipsychotic drug-induced hyperprolactinemia
  231. Potential biomarkers of tardive dyskinesia: a multiplex analysis of blood serum
  232. Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson’s disease
  233. Association of polymorphism in the dopamine receptors and transporter genes with hyperprolactinemia in patients with schizophrenia
  234. Gene polymorphisms of enzymes biotransformation of xenobiotics in patients with depressive disorders
  235. Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia
  236. Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease
  237. Olfaction, pain sensitivity and immunoendocrine system in substance use disorders
  238. THE BEHAVIOR STRATEGIES IN SITUATIONS OF DISORDER AND MEASURES CONTRIBUTING HEALTH CONDITIONS OF PATIENTS WITH MENTAL ILNESSES COMBINED WITH COMORBID DEPRESSION SYNDROME
  239. Clinical-immunological predictors of prognosis of the efficiency of antipsychotic therapy with amisulpride in schizophrenia
  240. Neurohumoral markers that predict the efficiency of pharmacologic therapy of depressive disorders
  241. Prolactin gene polymorphism (− 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics
  242. Association Between Prolactin Gene Polymorphism (–1149 G/T) and Hyperprolactinemia in Anti-psychotic Treated Patients with Schizophrenia
  243. Biomarkers of depressive disorders: A multiplex analysis of blood serum
  244. Clinical Variants of Psychopathological Disorders in Users of Synthetic Cannabinoids (Spices)
  245. Effect of original anticonvulsant meta-chloro-benzhydryl-urea on behavioral and immune parameters in mice with active and passive behavior types in experimental alcoholism
  246. Effect of Prenatal Exposure to Alcohol on the Development of Brain Vessels in Human Embryos and Fetuses
  247. Evaluation of dynamics of neurocognitive indicators and pathological craving in patients with dependence on synthetic cannabinoids during use of microwave resonance therapy
  248. Factors of premorbid period indicating the risk of medicated noncompliance in patients with schizophrenia
  249. Molecular targets of the ethanol and original anticonvulsant in the treatment of alcohol dependence
  250. Morphophenotypical patterns in patients with negative symptoms in schizophrenia
  251. Women with hysterical manifestations: Menopause, gender and mental health
  252. Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders
  253. Association of polymorphic variants of PIP5K2A and HTR2C genes with response to antidepressant therapy of patients with a current depressive episode
  254. Association study of genetic markers of schizophrenia and its cognitive endophenotypes
  255. Gender aspects of medico-social adaptation in adults with early onset of epilepsy
  256. Indices of the antioxidant system and dopamine in blood plasma in the dynamics of microwave resonance therapy in patients with alcoholism
  257. Association of СОМТ gene polymorphisms with Parkinson’s disease
  258. Нейрогуморальные маркеры прогноза эффективности фармакотерапии депрессивных расстройств, "Нейрохимия"
  259. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
  260. Gene polymorphism of neurotransmitter transporters in schizophrenic patients with drug-induced hyperprolactinemia
  261. Gene polymorphism of serotonin receptors and drug-induced hyperprolactinemia in schizophrenic patients
  262. Association of PIP5K2A and SGK1 genes with drug-induced dyskinesia in patients with schizophrenia
  263. CYP2D6 and catechol-O-methyltransferase gene polymorphisms in Parkinson patients with levodopa-induced dyskinesias
  264. Dynamics of neurohumoral factors in patients with depressive disorders in the treatment with selective serotonin reuptake inhibitors
  265. Gene polymorphisms of cytochrome P450, 1A2, 2D6 and drug-induced tardive dyskinesia in Russian patients with schizophrenia
  266. Neurohormonal factors of atypical depression
  267. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia
  268. FEATURES OF COGNITIVE RESOURCES OF COPING WITH DIFFICULT LIFE SITUATIONS IN REPRESENTATIVES OF ETHNIC GROUPS OF SIBERIA
  269. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group
  270. Agression of adolescents who comnmit offenses
  271. Cognitive functioning in alcoholic patients and efficiency of their correction with use of individualized therapy
  272. Therapeutic efficacy of original anticonvulsant meta-chloro-benzhydrylurea (m-ch-BHU) in the treatment of patients with a compulsive craving for alcohol
  273. not-labeling of psychiatry and mental patients
  274. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects
  275. Disrupted homeostasis during chronic ethanol consumption associated with specific mechanism of endogenous neurosteroids activity
  276. Neuroleptic effect in aggressive mice after the transplantation of immune cells treated in vitro with chlorpromazine
  277. Russian Federation
  278. Antioxidant and Immunotropic Properties of some Lithium Salts
  279. Treatment of Alcoholic Patients Using Anticonvulsant Urea Derivative Influences the Metabolism of Neuro-active Steroid Hormones - The System of Stress Markers
  280. Use of Carnosine for Oxidative Stress Reduction in Different Pathologies
  281. The Effect of Chronic Alcohol Abuse on the Benzodiazepine Receptor System in Various Areas of the Human Brain
  282. An effect of quetiapine on the immune system of patients with schizophrenia
  283. PSYCHOMETRIC EVALUATION OF SYMPTOMS AND CLINICAL DYNAMICS OF SCHIZOPHRENIA IN DEPENDING ON CONSTITUTIONALLY-MORPHOLOGICAL TYPE OF THE PATIENTS
  284. Antibodies to native and denatured DNA in the serum of patients with schizophrenia depending on the clinical features of the disease
  285. The association of the DRD3 gene with Parkinson’s disease
  286. The Influence of Alcohol Addiction on Cognitive Functions of the Representatives of Indigenous Population of Siberia
  287. An association of AKT1 gene polymorphism with antidepressant treatment response
  288. Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy
  289. Association of Cytokine Production with Hormone Level and Sensory Responses during the Formation of Psychoactive Drug Addiction in Men
  290. Association of drd3 gene polymorphisms with parkinson's disease (PD)
  291. Влияние адамантилбромфениламина на параметры иммунитета и симптомы астении у пациентов с непсихотическими психическими расстройствами
  292. DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia
  293. P.3.b.018 Gene polymorphisms of oxidative stress and glutamatergic system in schizophrenic patients with tardive dyskinesia
  294. P.5.d.005 Polymorphisms of DRD2, DRD3, DRD4 and HTR2C genes in levodopa-induced dyskinesias in Parkinson's disease
  295. Characteristics of membrane-bound pool of leukocyte lactate dehydrogenase in healthy men of different age
  296. Ethnoterritorial Heterogeneity of Formation of Alcohol Dependence in Native Population of Siberia
  297. Cytochrome P450 System Activity in Alcoholic Patients From Different Ethnic Groups
  298. Brain-derived Neurotrophic Factor in Patients with Affective Disorders
  299. Use of Traditional and Atypical Neuroleptics in Therapy of Psychoses Caused by Use of Synthetic Drugs
  300. Serum Levels of Neurosteroids in Patients with Affective Disorders
  301. New Approaches to the Treatment Alcohol Addiction in Experimental Alcoholism
  302. Role of Benzodiazepine Receptor Plasticity Associated with Neuroactive Steroid's Levels in Patients with Compulsive Craving for Alcohol, New Approaches to Therapy
  303. CLINICAL AND SOCIAL RISK FACTORS OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING ANTIPSYCHOTIC TREATMENT
  304. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility
  305. Analysis of alcohol dependence in indigenous peoples in Northern Siberia.
  306. Association between pathological olfaction, immunological abnormalities and predisposition to substance use
  307. Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
  308. P.2.a.008 Correlation between levels of Akt1/GSK-3β signaling pathway proteins and severity of depressive symptoms
  309. P.6.b.006 Carnosine protects blood plasma proteins from damaging effect of acetaldehyde
  310. P.1.g.051 Benzodiazepine receptor system in the brains of rats with experimental alcoholism and treatment effect of a novel anticonvulsant
  311. Proteins of the Akt1/GSK-3β signaling pathway in peripheral blood mononuclear cells of patients with affective disorders
  312. Ratio of Antibodies to Neurotransmitters in the Serum of Students, Occasional Drug Users
  313. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia
  314. Effect of Meta-Chlorobenzhydryl Urea (m-ClBHU) on Benzodiazepine Receptor System in Rat Brain During Experimental Alcoholism
  315. Neurophysiological Patterns of Search and Creative Behavior in Patients with Psychoactive Substance-Induced Disorders
  316. Glutamate Concentration in the Serum of Patients with Schizophrenia
  317. Glucose-6-phosphate dehydrogenase and catalase activities in erythrocytes of schizophrenic patients under pharmacotherapy with traditional antipsychotics
  318. P.6.a.005 Density of thrombocyte benzodiazepine receptors and levels of neuroactive steroid hormones in alcoholic patients
  319. Features of EEG in patients with disorders due to psychoactive substance use during olfactory stimulation
  320. Psychological Defense and Strategies of Coping in Alcohol Dependence and Co-Dependence in Women
  321. 1579 – Migration and mental health of aborigines of siberia: new challenges of old problems
  322. 1581 – Steroid hormones levels in alcohol dependent patients under conditions of social isolation
  323. 491 – Efficacy of original anticonvulsant galodif in treating of patients with compulsive craving to alcohol, associated with alteration levels of steroid hormons
  324. Conformational Stability of Leukocyte Lactate Dehydrogenase in Healthy Men of Different Age
  325. Neurosteroids Dehydroepiandrosterone and Its Sulfate in Individuals with Personality Disorders Convicted of Serious Violent Crimes
  326. P.6.a.006 A new original anticonvulsant decreases alcohol motivation and alters progesterone level in plasma of alcoholic patients
  327. P-14 - Dissociative mechanisms of formation of alcoholism in patients with co-morbid posttraumatic stress disorder
  328. Gender Heteronomy of the Formation of Heroin Addiction in Adolescents
  329. P.6.b.007 Influence of ethanol on synaptic benzodiazepine receptors and forming synapses in embryo's brain of alcoholic women
  330. P.6.b.006 Pharmacokinetic peculiarities of antipirine during treatment of alcoholic patients
  331. P.6.008 Neuropeptide in treatment of alcoholism: effect on psychological functions and lymphocyte apoptosis
  332. Influence of original anticonvulsant on pharmacometabolizing function of liver in patients with alcoholism
  333. P01-12 - Clinical prognosis of associated forms of alcoholism with co-morbid brain impairment
  334. P01-106 - Neuromorphologic and neurochemical regularities of prenatal exposure of developing human brain to alcohol
  335. P.6.a.007 Influence of neuroactive peptidic preparations on apoptosis of immunocompetent cells in alcoholic patients
  336. P.3.c.050 Interaction between polymorphisms of oxidative enzymes and susceptibility to tardive dyskinesia in psychiatric patients
  337. Spontaneous and In Vitro Induced Apoptosis of Lymphocytes and Neutrophils in Patients with Alcohol Dependence
  338. P02-80 - Steroid hormones in patients with personality disorders in conditions of social isolation
  339. PW01-218 - Apoptosis of lymphocytes in alcoholic patients during withdrawal syndrome therapy
  340. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia
  341. P.6.b.004 Apoptosis of immunocompetent cells in patients with alcoholism in dynamic of therapy
  342. P.6.b.006 Peripheral benzodiazepine receptor in platelets of alcoholic patients as a test of efficacy of antialcohol drugs
  343. Effects of Microwave Resonance Therapy on Erythrocyte and Plasma Proteins and Lipids in Alcoholics
  344. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia
  345. P.6.d.012 Immune system in opioid addicts
  346. P.3.d.011 Immunotropic effects of atypical neuroleptics olanzapine and amisulpride
  347. P.6.b.003 Anticraving-therapy of alcoholism in patients with comorbid arterial hypertension: abilities of paroxetine
  348. P.3.c.044 Tardive dyskinesia and polymorphism of dopamine D3, serotonin 2A and 2C receptors in Russian psychiatric inpatients
  349. P.6.b.008 Treatment of alcoholic patients with original anticonvulsant alters alcohol motivation and progesterone level in plasma
  350. Gender-associated patterns of heroin addiction in adolescents
  351. Anticonvulsive properties of M-chlorbenzhydrilurea and prospect of its clinical application
  352. Kinetic of a new drug in patients with alcoholism
  353. The influence of the Antioxidant Carnosin on the intensity of the alcoholic patients pathological addiction to alcohol during rehabilitation period
  354. P.1.b.003 Anticonvulsive drug kinetic in patients with alcoholism
  355. Comorbidity and therapy of affective disturbances in associated forms of alcoholism
  356. Erythrocyte and plasma protein modification in alcoholism: A possible role of acetaldehyde
  357. Raised cortisol:DHEAS ratios in the elderly after injury: potential impact upon neutrophil function and immunity
  358. P.6.063 Clinical and biological effectiveness of anar therapy in opiate addicts
  359. P.1.045 Psychotropic drugs and homeostatic systems: Mechanism of psychoneuroimmunomodulation
  360. P.6.032 Pica, anxiety and addiction: Mechanismsand therapy
  361. P.6.064 Influence of alcohol dependence on oxidative metabolism of xenobiotics in humans
  362. Effect of carnosine on immunocompetent cells from alcoholic patients
  363. Immunity system in alcoholism
  364. COMORBIDITY OF AFFECTIVE DISTURBANCES IN ASSOCIATED FORMS OF ALCOHOLISM.
  365. Effects of antioxidant carnosine on immunity in addiction
  366. IN VITRO EFFECTS OF ETHANOL, ACETALDEHYDE AND FATTY ACID ETHYL ESTERS ON HUMAN ERYTHROCYTES
  367. Therapeutic efficiency coaxil at treatment of alcoholism
  368. EFFECTS OF CARNOSINE AND RELATED COMPOUNDS ON THE STABILITY AND MORPHOLOGY OF ERYTHROCYTES FROM ALCOHOLICS
  369. Efficacy of finlepsin-retard by alcoholism with comorbld brain impairment
  370. Olfaction, nociception and immunity in mental disorders
  371. Sensory systems and immunity in mental disorders